This Quarterly Report on Form 10-Q contains forward-looking statements. All statements other than statements of historical fact are "forward-looking statements" for purposes of this Quarterly Report on Form 10-Q. These forward-looking statements may include, but are not limited to, statements regarding our future results of operations and financial position, business strategy, market size, potential growth opportunities, timing and results of preclinical and clinical development activities, selection of specific financial and strategic alternatives, and potential regulatory approval and commercialization of products and product candidates. In some cases, forward looking-statements may be identified by terminology such as "believe," "may," "will," "should," "predict," "goal," "strategy," "potentially," "estimate," "continue," "anticipate," "intend," "could," "would," "project," "plan," "expect," "seek" and similar expressions and variations thereof. These words are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, research and development, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in the "Risk Factors" section and elsewhere in this Quarterly Report on Form 10-Q. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Quarterly Report on Form 10-Q may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to actual results or to changes in our expectations, except as required by law. As used in this Quarterly Report on Form 10-Q, the terms "Obalon," "the Company," "we," "us," and "our" refer to
Obalon Therapeutics, Inc.and, where appropriate, its consolidated subsidiary, unless the context indicates otherwise. You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated financial statements and related notes included in Part I, Item 1 of this Quarterly Report on Form 10-Q and with our audited consolidated financial statements and related notes thereto for the year ended December 31, 2019, included in our Annual Report on Form 10-K for the year ended December 31, 2019, filed on February 27, 2020. OVERVIEW We are a vertically integrated medical device company focused on developing and commercializing innovative medical devices to treat people with obesity. Our current product offering is the Obalon Balloon System, the first and only U.S. Food and Drug Administration, or FDA, approved swallowable, gas-filled intragastric balloon designed to provide progressive and sustained weight loss in patients with obesity. We believe the Obalon Balloon System offers patients and physicians benefits over prior weight loss devices including, but not limited to, clinically meaningful weight loss, a favorable safety profile, improved patient tolerability and comfort, progressive weight loss with durable results, simple and convenient placement, and potentially attractive economics. The Obalon Balloon System is FDA approved for temporary use to facilitate weight loss in adults with obesity having a body mass index, or BMI, of 30 to 40, or approximately 30 to 100 pounds overweight, who have failed to lose weight through diet and exercise. The system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed six months after the first balloon is placed. We believe the Obalon Balloon System provides a cost-effective, non-surgical and reversible weight loss solution in an outpatient setting. The Obalon Balloon System consists of a swallowable capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement without x-ray; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with our proprietary mixture of gas. Placement of a balloon typically occurs in less than 15 minutes and can be accomplished in an outpatient setting without the 20
-------------------------------------------------------------------------------- need for anesthesia or sedation. Patients receive a total of three balloons over the course of eight to 12 weeks and all balloons are removed six months after the first balloon is placed. In clinical studies, the Obalon Balloon System has demonstrated clinically meaningful weight loss with durable results. In addition, data published and presented from our commercial registry demonstrates greater weight loss in the commercial setting as compared to our pivotal clinical study used to support FDA approval. In our published pivotal SMART trial, patients in the Obalon treatment group lost, on average, approximately twice as much body weight as patients in the sham-control group, with an average of 15.1 pounds of weight loss, resulting in an average 6.9% reduction in total body weight and an average 2.4 point decrease in BMI. 66.7% of patients lost at least 5% of their total body weight (%TBWL) and the study showed statistically significant improvements in cardiometabolic risk factors, including fasting glucose, systolic blood pressure, cholesterol and triglycerides. Patients in the treatment group were followed for 48 weeks and showed, on average, 89.5% of the weight loss achieved during the initial 24 week balloon treatment period was maintained at 48 weeks, or 24 weeks after the balloons were removed. In
December 2018, data from our commercial registry was analyzed, and later published and presented, on more than 1,300 patients at 108 treatment sites. For those patients who received three balloons and at least 20 weeks of therapy, the average weight loss was 21.7 pounds, resulting in 9.9% reduction in total body weight and a 3.5 point decrease in BMI compared to baseline values. Of note, the top quartile of those patients lost an average of 39 pounds, resulting in an average of 16.8% reduction in total body weight and an average of a 6.2 point decrease in BMI compared to baseline values. Furthermore, in May 2019, analysis of data from our commercial registry was updated to include 1,411 total patients from 143 treatment sites in the United States. In this larger data set, for those patients receiving three balloons and at least 20 weeks of therapy, the average weight loss was 21.7 pounds, resulting in a 10.2% reduction in total body weight. Of note, 50.7% of patients lost 10% or more total body weight and 77.9% lost 5% or more total body weight. We commenced U.S.commercialization of our prior generation Obalon balloon system in January 2017. In February 2019, we commercialized our current generation Obalon Balloon System with the Obalon Touch Inflation Dispenser and our Obalon Navigation System, which together are designed to make balloon placements more reliable, safer, easier and less expensive. The Obalon Navigation System is designed to eliminate the need to use x-ray technology when placing the Obalon balloon. When we commenced our U.S.commercial launch in 2017, we relied on a small direct sales force to sell our products directly to physicians, who would then sell weight loss treatment packages to their patients that included our balloon therapy, dietary counseling and balloon removal on a non-reimbursed, self-pay basis for patients. In 2019, we began implementing a fundamental change to our commercialization efforts, pursuant to which we eliminated our direct sales force and began establishing Company-owned or managed Obalon-branded retail treatments centers. We also transitioned to a centralized customer support model through which we sold to existing physician customers or new physicians that contacted us directly to acquire the Obalon Balloon System and provided centralized marketing and clinical support to those physicians. In March 2020, we announced that the overall uncertainty, the restriction on elective procedures and the specific directives issued by the Governor of Californiaas a result of COVID-19 had a significant impact on our business. As a result, we halted sales to new patients in our company-branded retail treatment centers, terminated expansion plans for additional retail centers and subsequently closed the two retail treatment centers we had opened. We have also halted manufacturing operations and have not filled orders to U.S.customers or our former international distributor since that time. Additionally, we terminated our contract with Al Danah, our only international distributor. In June 2020, we temporarily restarted manufacturing on a limited basis to convert our work in progress inventory to finished goods in order to have units available for clinical trials and unexpected physician sales but do not expect to continue manufacturing past June 30, 2020. Additionally, we expect that, after a transition at the end of July 2020, only two full-time employees will remain: Andy Rasdal, our President and Chief Executive Officer, and Nooshin Hussainy, our Chief Financial Officer. Given those impacts and the significant concern about an economic recovery that would allow consumers to feel confident enough to spend on a cash-pay procedure like the Obalon Balloon System, we do not currently plan to re-open our retail treatment centers, re-initiate our retail treatment center expansion plans, or plan to ship orders to U.S.customers or our former international distributor. As a result, we would not expect to report any meaningful revenue for the foreseeable future. We continue to believe the Obalon Balloon System can provide significant benefits to patients and value to the healthcare system. However, treatment with the Obalon Balloon System is not currently covered by any kind of private or public health insurance. We believe this has contributed to slow commercial adoption of the product and the procedure, as physicians are not reimbursed for treating patients with the Obalon therapy and patients must pay solely out of pocket for the Obalon Balloon System and the placement procedure. With that in mind, we are initiating efforts to explore obtaining third-party payor reimbursement and coverage for the Obalon Balloon System. We believe that reimbursement and coverage for the Obalon 21 -------------------------------------------------------------------------------- Balloon System could significantly expand our market opportunity. There are more than 70 million adults in the United Stateswho are obese and over 11 million adults in the United Stateswho have Type 2 diabetes and are obese. Moreover, the COVID-19 pandemic has further highlighted the personal health and economics costs of the obesity epidemic in the United States. Recently published data suggest that next to age, the underlying health conditions of obesity and obesity-related health conditions (hypertension and diabetes) are the greatest predictors of COVID-19 hospitalizations and death. We believe the Obalon Balloon System could help reduce third-party payors' costs and improve patient care, and we intend to explore how additional data may be collected to demonstrate the economic and clinical evidence necessary to secure reimbursement. However, obtaining reimbursement is never certain and can take many years to achieve, and if achieved, may not be determinative of our success. If our initial efforts with payors begin to bear success, we would expect to need to raise additional capital to support those efforts. To enable us to pursue this reimbursement strategy, we are taking further steps to significantly reduce expenses in an effort to extend our cash runway. We have significantly reduced the organization to only essential personnel. During this time we also plan to continue to explore other potential business options and strategic alternatives. We generated total revenue of $0.7 millionand $0.4 millionfor the three months ended June 30, 2020and 2019, respectively, and $1.5 millionand $2.2 millionfor the six months ended June 30, 2020and 2019, respectively. We have incurred significant losses in each period since our inception in 2008, with net losses of $4.2 millionand $6.8 millionduring the three months ended June 30, 2020and 2019, respectively, and $9.4 millionand $15.1 millionduring the six months ended June 30, 2020and 2019, respectively. We have not been profitable since inception, and as of June 30, 2020, our accumulated deficit was $181.9 million. On April 22, 2020, we executed a promissory note in favor of Silicon Valley Bankevidencing an unsecured loan in the aggregate principal amount of $0.4 million, which was made pursuant to the Paycheck Protection Program and which we refer to as the PPP Loan. The Paycheck Protection Program was established under the Coronavirus Aid, Relief and Economic Security Act , which was enacted on March 27, 2020, and is administered by the U.S. Small Business Administration. All the funds under the PPP Loan were disbursed to us on April 23, 2020. Our consolidated financial statements as of and for the three and six months ended June 30, 2020have been prepared on the basis that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Based on our cash balances and recurring losses since inception, there is substantial doubt about our ability to continue as a going concern Our ability to continue as a going concern, and correspondingly to execute on our business plan and strategy, is dependent upon our ability to accomplish one or more of the following: raise additional capital in the very near term to fund our ongoing operations or engage in a strategic alternative. If we are not able to accomplish one or more of these goals in the near term, there is a high likelihood we may need to sell all or portions of our business, liquidate all or some of our assets or seek bankruptcy protection, which could result in significant decrease in value for all stakeholders. COMPONENTS OF OUR RESULTS OF OPERATIONS Revenue For the three and six months ended June 30, 2020and 2019, revenue reflects sales of our Obalon Balloon System directly to physicians and institutions in the United States, sales of our Obalon Balloon System to our Middle Eastdistributors, and sales from patients treated at our Company-managed Obalon-branded retail center. We also generated revenue during the six months ended June 30, 2020from reversing various reserves related to revenue from customer incentive programs, swallow guarantee, and returns reserves as a result of terminating all commercial operations and underlying programs. We do not currently plan to re-open our retail treatment centers, re-initiate our retail treatment center expansion plans, restart manufacturing operations, or plan to ship orders to U.S.customers or our former international distributor. As a result, we would not expect to report any meaningful revenue for the foreseeable future. To date we have experienced limited penetration of the U.S. market, and there are many factors that may impact our future results of operations, including: our ability to establish coverage and reimbursement for the Obalon Balloon System, our ability to successfully develop the intragastric balloon market (which is currently small and immature) and gain acceptance of our current Obalon Balloon System and its future iterations by doctors and patients, our ability to scale production in a cost effective manner or if at all should we restart manufacturing operations, the emergence of competing products, actions by regulatory bodies, and general economic trends. The amount of revenue and timing of revenue recognition may also be impacted by any future com 22 --------------------------------------------------------------------------------
modèle économique et programmes d'incitation à la clientèle que nous avons décidé d'offrir et
canaux par lesquels les revenus sont tirés.
Coût des revenus et marge brute
Cost of revenue consists primarily of costs related to the direct materials and direct labor that are used to manufacture our products and the overhead costs that directly support manufacturing. Currently, a significant portion of our cost of revenue consists of manufacturing overhead, which is mostly fixed in nature. These overhead costs include the costs of compensation for operations management, engineering support, material procurement and inventory control personnel, outside consultants, production related supplies, allocated quality assurance and facilities costs, and depreciation on production equipment. In the foreseeable future, we expect cost of revenue to be higher than revenue as we focus on reimbursement activities rather than commercial sales. We calculate gross margin as gross profit divided by revenue. Our gross margin has been and will continue to be affected by a variety of factors, primarily production volumes, geographic mix, product mix, manufacturing costs, product yields, headcount and cost-reduction strategies. We expect gross margin to fluctuate from quarter to quarter due to variability of our recognized revenue, our adoption of new manufacturing processes and technologies, changes in our manufacturing capacity, and discontinuation of obsolete products. We have experienced challenges in our ability to produce finished goods, which may impact our ability to meet the demands for future commercial and clinical trials. In
March 2020, we suspended manufacturing of the Obalon Balloon System due to the ongoing COVID-19 pandemic. We restarted manufacturing on a limited basis in June 2020to convert a small amount of work-in-progress inventory to finished goods, in order to have units available for clinical trials and unexpected physician sales. As of June 30, 2020our manufacturing operations have been suspended with no future plans for restarting. Research and development expenses Research and development, or R&D, expenses consist of the cost of engineering, clinical affairs, regulatory affairs and quality assurance associated with developing our Obalon Balloon System. R&D expenses consist primarily of: • employee-related expenses, including salaries, benefits, travel expense and stock-based compensation expense; • cost of outside consultants who...
Meilleure Vente n° 1
Arkopharma Detox + Starter & Booster Minceur Bio 3 x 10 Ampoules 10 ml
- permet en 3 étapes de perdre du poids et de le stabiliser
- En 30 jours, l'organisme est purifié et la taille s'affine
- prendre 1 ampoule le matin en diluant dans un verre d’eau ou de jus de fruits
- fabriqué en France
Meilleure Vente n° 2
Mon programme minceur 30 jours
- 144 Pages - 06/10/2020 (Publication Date) - Larousse (Publisher)
PromoMeilleure Vente n° 3
CURE MINCEUR 21 JOURS BRÛLE-GRAISSE NATURELLE ET EFFICACE. A Base de Légumes et de Soupe au Chou. Perte de Poids Rapide et Durable pour Homme et Femme. Vegan, Sans Gluten et Fabriqué en France.
- ✅ PLUS DE 3 MILLIONS DE CLIENTS SATISFAITS DEPUIS 1999. Faites le plein de vitamines, de fibres, de saveurs gustatives, le détox en plus et vous êtes en route pour la minceur en 7 jours seulement. Amincissement perceptible dès les premiers jours
- ✅ CURE MINCEUR BRULE GRAISSE CLINIQUEMENT TESTEE pour Homme et pour Femme. Notre méthode permet de consommer deux fois moins de calories par jour que les besoins nutritionnels normaux, résultats, le corps va puiser dans ses réserves de graisses. Perdez en moyenne 3,1 kg en 7 jours seulement et 9,1 kg en moyenne sur 21 jours !
- ✅ BONNE, NUTRITIVE, NATURELLE ET SAINE. A base de choux qui est un brûle graisse naturelle. 29 Kcal par portion destinée à un régime pour perdre du poids, riche en fibres, pauvre en sucre, sans matière grasse, sans gluten. Vegan, riche en vitamines, calcium, magnésium, potassium, phosphore. Laboratoire certifié ISO 9001. Fabriqué en France.
- ✅ PRATIQUE. Ce shake diététique, se prépare en potage ou en cocktail santé-forme et minceur mélangé avec de l’eau ou avec un lait ou une boisson végétale pour varier les goûts selon votre humeur...
- ✅ Dans votre boite, 3 sachets de 300 grammes pour 21 JOURS DE CURE MINCEUR (-9,1 kg en moyenne) + UN LIVRET METHODE MINCEUR OFFERT. Avec des Conseils, une conduite alimentaire saine et équilibrée, et des exercices physiques à faire chez soi
PromoMeilleure Vente n° 4
Santarome Bio Programme Ultra Minceur 30 Ampoules Complément Alimentaire Perte de Poids 30 Jours
- Programme perte de poids bio
- Formule 100% bio et 100% Vigan à base de 9 plantes + 3 bourgeons: ananas, Guarana, cassis, bardane, chardon-marie, reine des prés, pissenlit, thé vert, café vert + bouleau, frêne et cassis
- Prendre 1 ampoule par jour, en suivant l'ordre des étapes, diluée dans un verre d’eau (20 Cologne) au moment du repas
- Fabriqué en France
Meilleure Vente n° 5
AGENDA MINCEUR 90 Jours: Journal alimentaire et d’activité sportive (Bleu)
- 102 Pages - 07/07/2017 (Publication Date) - CreateSpace Independent Publishing Platform (Publisher)
PromoMeilleure Vente n° 6
LINEAVI Principes Actifs Minceur, substitut de repas en poudre, combination des protéines: soja, riz, petits pois et petit-lait, sans lactose et sans gluten, fabriqué en Allemagne, 3x500g + shaker
- POUR LE PROGRAMME MINCEUR LINEAVI DE 2 SEMAINES: Le pack est constitué de trois boîtes de 500g comprenant 30 repas et d'un shaker gratuit.
- PRINCIPES ACTIFS MINCEUR: LINEAVI est un substitut de repas pour contrôle du poids avec sucres et édulcorant (207 kcal par portion).
- COMBINAISON DES PROTÉINES: Protéines - obtenues à partir du soja, des petits pois, du riz et du petit-lait - contribuent au maintien de la masse musculaire.
- AVEC VITAMINES, MINÉRAUX, FIBRES: Vitamine B6, B12, thiamine, calcium et fer contribuent à un métabolisme énergétique normal.
- ORIGINE CONTRÔLÉE, MADE IN GERMANY : Nos produits sont fabriqués et contrôlés selon des normes stricts (ISO 9001, HACCP, BPF).
Meilleure Vente n° 7
Mon objectif minceur : Pour maigrir semaine après semaine
- 208 Pages - 05/01/2019 (Publication Date) - FLAMMARION (Publisher)
Meilleure Vente n° 8
BEAVITA Vitalkost Plus Vanille - Substitut de Repas 3 x 500g – Programme Minceur en 14 jours – Shake délicieux accompagnant un régime – Sans Gluten Sans Substitut de Sucre
- BON POUR LA SANTÉ : notre substitut de repas Vitalkost Plus contient moins de 205Kcal par repas, pour un goût absolument délicieux !
- PRINCIPES ACTIFS MINCEUR : la poudre Vitalkost Plus constitue un repas idéal dans le cadre d'une alimentation pour un contrôle du poids. En lien avec une alimentation pauvre en calories, notre substitut de repas contribue à la perte de poids lorsqu'il remplace deux repas par jour
- PRODUIT 100% BRUT : contient de nombreux ingrédients de haute qualité comme des enveloppes de psyllium, de la gomme de caroube et du miel - contribue au maintien de la masse musculaire
- RICHE EN PROTÉINES : notre substitut de repas BEAVITA Vitalkost Plus contient tous les nutriments essentiels et 40% de protéines
- EXCELLENTS RAPPORTS QUALITÉ/PRIX & QUANTITÉ/PRIX : chaque boîte représente l'équivalent de 10 repas (dans les proportions recommandées)
Meilleure Vente n° 9
Juvamine BRULE GRAISSE - PROGRAMME MINCEUR, 60 gélules
- Complément alimentaire à base de thé vert, de café vert et de kola
- Le thé vert est reconnu pour contribuer à la perte de poids et à l'oxydation des graisses
- Le Café vert est non torréfié
- Le Kola complète la formule
- Contient 60 gélules
Meilleure Vente n° 10